UBS O'Connor’s OncoSec Medical Incorporated ONCS Stock Holding History

UBS O'Connor’s Portfolio ONCS Stock Details ONCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,225	Closed	-$507K	–	402
2018 Q1	$507K	Buy	+1,225	New	+$503K	0.01%	262

Other funds holding ONCS

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

UBS O'Connor's ONCS Position: Q2 2018 in Review

UBS O'Connor sold out of OncoSec Medical Incorporated (ONCS) in Q2 2018, closing a stake of 1,225 shares — an estimated $507K sold.

UBS O'Connor first reported a position in ONCS in Q1 2018 and held it in 1 quarter. The position peaked at $507K in Q1 2018. 34 funds tracked by Wall St. Rank hold ONCS as of Q2 2018.

UBS O'Connor reported no remaining OncoSec Medical Incorporated position as of Q2 2018 after selling out during the quarter.
UBS O'Connor sold 1,225 OncoSec Medical Incorporated shares in Q2 2018, an estimated $507K.
UBS O'Connor first reported a position in OncoSec Medical Incorporated in Q1 2018 and held it in 1 quarter.
UBS O'Connor's OncoSec Medical Incorporated position peaked at $507K in Q1 2018.
34 funds tracked by Wall St. Rank held OncoSec Medical Incorporated as of Q2 2018.

Based on UBS O'Connor's 13F filing for Q2 2018, filed 14 Aug 2018.